Cannabis use after a cancer diagnosis in a population-based sample of cancer survivors
- 22 March 2024
- journal article
- research article
- Published by Springer Nature in Cancer Causes & Control
- Vol. 35 (7) , 1033-1042
Abstract
Purpose This study aimed to characterize the prevalence and correlates of cannabis use and the methods and reasons for use among recently diagnosed cancer survivors in a population sample within Washington state. Methods We identified individuals diagnosed with invasive cancers in the prior 6 to 17 months from April 2020 to December 2020 using the Seattle-Puget Sound Surveillance, Epidemiology, and End Results (SEER) cancer registry. Participants (n = 1,515) completed a questionnaire, including demographics, medical history, cannabis use, and other substance use. Cancer characteristics and date of diagnosis were obtained from SEER registry data. We calculated weighted prevalence estimates and logistic regression models to evaluate correlates of cannabis use. Results Overall, 41.3% of survivors reported cannabis use at any time after diagnosis, most commonly via edibles (60.5%) and smoking (43.8%). The most frequently reported reasons for use were sleep (54.5%), mood, stress, anxiety, and depression (44.3%), pain (42.3%), and recreation (42.3%). Cannabis use was associated with younger age, race (White vs. Asian), less education, former or current smoking, consuming more than 2 alcohol-containing drinks per day, having late-stage cancer, and cancer site. Conclusion In this first evaluation of cannabis use in a registry-linked, population-based sample of survivors of all cancer types, based in a state where recreational and medical cannabis have been legal for a decade, approximately 2 in 5 survivors reported post-diagnosis use. Given how common cannabis use is among cancer survivors, there is a great need to understand its impact on cancer treatment outcomes and the overall health of cancer survivors.Keywords
Funding Information
- National Institutes of Health (T32 CA916845, 3P30 CA015704-45S8)
This publication has 25 references indexed in Scilit:
- MASCC guideline: cannabis for cancer-related pain and risk of harms and adverse eventsSupportive Care in Cancer, 2023
- Multinational Association of Supportive Care in Cancer (MASCC) guidelines: cannabis for psychological symptoms including insomnia, anxiety, and depressionSupportive Care in Cancer, 2023
- Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/consensus guidance on the use of cannabinoids for gastrointestinal symptoms in patients with cancerSupportive Care in Cancer, 2022
- In the weeds: a retrospective study of patient interest in and experience with cannabis at a cancer centerSupportive Care in Cancer, 2022
- Marijuana use among US adults with cancer: findings from the 2018–2019 Behavioral Risk Factor Surveillance SystemJournal of Cancer Survivorship, 2022
- Cannabis use among cancer survivors in the United States: Analysis of a nationally representative sampleCancer, 2021
- Cannabis use is associated with patient and clinical factors in a population-based sample of colorectal cancer survivorsCancer Causes & Control, 2021
- Prevalence of cannabis use among individuals with a history of cancer in the United StatesCancer, 2021
- Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational useCancer, 2017
- The AUDIT Alcohol Consumption Questions (AUDIT-C)An Effective Brief Screening Test for Problem DrinkingArchives of internal medicine (1960), 1998